Sex-specific cardiovascular risks of cancer and its therapies
In both cardiovascular disease and cancer, there are established sex-based differences in
prevalence and outcomes. Males and females may also differ in terms of risk of cardiotoxicity …
prevalence and outcomes. Males and females may also differ in terms of risk of cardiotoxicity …
Infertility in men: advances towards a comprehensive and integrative strategy for precision theranostics
M Assidi - Cells, 2022 - mdpi.com
Male infertility is an increasing and serious medical concern, though the mechanism
remains poorly understood. Impaired male reproductive function affects approximately half …
remains poorly understood. Impaired male reproductive function affects approximately half …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study
Background Although androgen deprivation therapy (ADT) is associated with cardiovascular
risks, the extent and temporal trends of cardiovascular burden amongst patients with …
risks, the extent and temporal trends of cardiovascular burden amongst patients with …
Permissive cardiotoxicity: the clinical crucible of cardio-oncology
The field of cardio-oncology was born from the necessity for recognition and management of
cardiovascular diseases among patients with cancer. This need for this specialty continues …
cardiovascular diseases among patients with cancer. This need for this specialty continues …
Reproductive milestones across the lifespan and cardiovascular disease risk in women
CA Stuenkel - Climacteric, 2024 - Taylor & Francis
Cardiovascular disease (CVD) is the leading cause of death for women across the
developed and developing world. Beyond traditional cardiovascular risk factors, a number of …
developed and developing world. Beyond traditional cardiovascular risk factors, a number of …
Cardiovascular disease and cancer: shared risk factors and mechanisms
Cardiovascular disease (CVD) and cancer are among the leading causes of morbidity and
mortality globally, and these conditions are increasingly recognized to be fundamentally …
mortality globally, and these conditions are increasingly recognized to be fundamentally …
Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms
D Pantazi, AD Tselepis - Thrombosis Research, 2022 - Elsevier
Cancer treatment is associated with various side effects of antitumor agents, which increase
the morbidity and mortality of these patients. Cardiovascular complications are considered to …
the morbidity and mortality of these patients. Cardiovascular complications are considered to …
Cardiovascular disease in adult cancer survivors: a review of current evidence, strategies for prevention and management, and future directions for cardio-oncology
Abstract Purpose of Review Cardiovascular disease is long-term complication of both
cancer and anti-cancer treatment and can have significant ramifications for health-related …
cancer and anti-cancer treatment and can have significant ramifications for health-related …